Citation | Devasthale, P; Wang, Y; Wang, W; Fevig, J; Feng, J; Wang, A; Harrity, T; Egan, D; Morgan, N; Cap, M; Fura, A; Klei, HE; Kish, K; Weigelt, C; Sun, L; Levesque, P; Moulin, F; Li, YX; Zahler, R; Kirby, MS; Hamann, LG Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778). J Med Chem56:7343-57 (2013) [PubMed] Article |
---|
SMILES | CNC(=O)Cn1cc2[nH]c(C)c(CN)c(-c3ccc(Cl)cc3Cl)c2c1=O |(25.56,-15,;24.02,-15.01,;23.25,-16.35,;21.71,-16.35,;24.03,-17.68,;25.57,-17.67,;26.48,-16.41,;27.95,-16.88,;29.28,-16.11,;30.61,-16.88,;31.95,-16.1,;30.62,-18.43,;31.96,-19.2,;33.29,-18.42,;29.29,-19.2,;29.28,-20.74,;27.95,-21.5,;27.94,-23.04,;29.27,-23.81,;29.27,-25.35,;30.61,-23.04,;30.61,-21.5,;31.94,-20.73,;27.96,-18.43,;26.49,-18.92,;26.02,-20.38,)| |